Loading stock data…
Forte Biosciences, Inc. (FBRX)
$54.78-4.92 (-8.24%)
Market ClosedLast close Jul 24
Forte Biosciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Forte Biosciences, Inc. in the Healthcare sector is trading at $54.78 with a market capitalization of $437M. Wall Street consensus targets $66.60 (5 analysts), implying a +21.6% move over the next 12 months. The stock is currently near its 52-week high of $62.46, remaining 120.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +21.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$22.44M↑ | -$24.57M↓ | -$18.38M↓ | -$11.58M↑ | -$16.12M |
| Net Income | -$22.14M↑ | -$24.79M↓ | -$17.68M↓ | -$11.25M↑ | -$15.66M |
Peer Comparison
JNJUNHPFE
Fundamentals
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and aut...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$436.61M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.87
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-180.18%
Volume
Today's trading volume
568,928
Recent News
Should You Be Bullish on Forte Biosciences (FBRX)?
Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States […]
TRAX Stock Hits All-Time High — What's Driving The Super Rally?
According to TheFly, HC Wainwright raised its price target on First Tracks to $44 from $30 while maintaining a ‘Buy’ rating.
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data
Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.
Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement
Forte Biosciences (NASDAQ:FBRX) said FB102 showed statistically significant improvement in a small placebo-controlled vitiligo study, with Chief Executive Officer Paul Wagner highlighting continued improvement after patients stopped treatment as a key feature of the results. On a company data call,
Forte Biosciences shares surge after positive phase 1b vitiligo results
Forte Biosciences (NASDAQ:FBRX) shares jumped about 55% after the company reported positive phase 1b clinical trial results for FB102, an investigational therapy for vitiligo, showing statistically significant improvements in disease severity compared with placebo. Vitiligo is a chronic...